2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Thyroid Disease

Thyroid Disease

Thyroid disease involves disorders of the thyroid gland, rare in rabbits and rodents but more commonly observed in guinea pigs, including hyperthyroidism and thyroid neoplasms.

 

Thyroid Disease (26):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13817
    IU1 314245-33-5 99.30%
    IU1 is a selective, reversible USP14 inhibitor with an IC50 of 4-5 μM. IU1 binds USP14’s catalytic cleft to block deubiquitinase activity. IU1 induces calpain-dependent Tau cleavage, causes ATP deficits, reduces E1~Ub thioester levels and 26S proteasome assembly. IU1 enhances 26S proteasome chymotrypsin-like activity, modulates LC3B-dependent autophagy flux, reduces cancer cell proliferation and migration, and blocks G0/G1 to S phase cell cycle transition in follicular thyroid cancer cells. IU1 activates autophagy-lysosomal and ubiquitin-proteasome pathways, triggers apoptosis, and reduces cervical cancer cell growth. IU1 enhances degradation of proteasome substrates linked to neurodegenerative disease, accelerates oxidized protein degradation, and increases oxidative stress resistance. IU1 can be used for the research of Alzheimer’s disease, follicular thyroid cancer, ischemic stroke, cervical cancer, and neurodegenerative disease.
    IU1
  • HY-P990534
    Anti-TSHR Antibody (K1-70) 98.57%
    Anti-TSHR Antibody (K1-70) is an anti-TSHR monoclonal antibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC).
    Anti-TSHR Antibody (K1-70)
  • HY-129046C
    RNase B, Bovine Pancreas
    RNase A (Bovine pancreatic RNase) is a widely used Endonuclease in DNA purification by specifically hydrolyzing cytosine or uracil residues of RNA. RNase A degrades the RNA in the RNA/DNA duplex. RNase A catalyses the breakdown of 3',5'-phosphodiester linkages of single stranded RNA. RNase A family members in organisms are tightly involved in various physiological and pathological processes including cell growth and development, proliferation, differentiation and migration. Dysregulation of RNase A activity or expression level is closely related to pancreatic, ovarian, bladder and thyroid cancer. RNase A has tumor cell-killing ability. RNase B, Bovine Pancreas (Ribonuclease B, Bovine Pancreas) is the N-glycosylated form of RNase A. RNase B, Bovine Pancreas can promote the folding of polypeptide chains and play a role similar to molecular chaperones.
    RNase B, Bovine Pancreas
  • HY-P99364
    Icrucumab 1024603-92-6 99.9%
    Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer.
    Icrucumab
  • HY-129046I
    RNase A, Recombinant (animal free) 9001-99-4
    RNase A (Bovine pancreatic RNase) is a widely used Endonuclease in DNA purification by specifically hydrolyzing cytosine or uracil residues of RNA. RNase A degrades the RNA in the RNA/DNA duplex. RNase A catalyses the breakdown of 3',5'-phosphodiester linkages of single stranded RNA. RNase A family members in organisms are tightly involved in various physiological and pathological processes including cell growth and development, proliferation, differentiation and migration. Dysregulation of RNase A activity or expression level is closely related to pancreatic, ovarian, bladder and thyroid cancer. RNase A has tumor cell-killing ability. RNase A, Recombinant (animal free) is recombinant RNase A with no animal-derived components.
    RNase A, Recombinant (animal free)
  • HY-181555
    IACS-56676 3105153-34-9
    IACS-56676 is a selective NRASG12D inhibitor with a target Kd of 0.031 μM. IACS-56676 stabilizes the p-loop, maintains key interactions with Asp12, Gly60 and Asp69, and achieves selectivity over wild-type KRAS through substitution targeting Leu95. IACS-56676 can be used for research on melanoma, hematologic malignancies and thyroid cancer.
    IACS-56676
  • HY-183684
    RET-IN-33
    RET-IN-33 (Compound CN-3) is a moderately selective inhibitor of RET mutants. RET-IN-33 potently inhibits G810 mutants, with IC50 values of 4.43 nM (G810R), 3.28 nM (G810C) and 0.51 nM (G810S), respectively. RET-IN-33 also inhibits other RET mutants: V804M (IC50 0.73 nM), V804L (IC50 0.36 nM), Y806H (IC50 0.74 nM) and M918T (IC50 0.55 nM). RET-IN-33 also inhibits other kinases, with an IC50 of 1.50 nM against VEGFR2 and 1.60 nM against PDGFRα. RET-IN-33 blocks the autophosphorylation of RET mutants and the downstream SHC/AKT/ERK signaling pathway. RET-IN-33 selectively inhibits the proliferation of RET-driven cell models without affecting non-RET-dependent or normal cells. RET-IN-33 exhibits dose-dependent antitumor efficacy in RET-driven xenograft models. RET-IN-33 can be used for the research of medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer.
    RET-IN-33
  • HY-180551
    ZW-6-052
    ZW-6-052 (compound 20), the derivative of ZW-18-116 (HY-180550), is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-6-052 induces degradation of TMP3-TRKA in KM12 mouse xenograft models. ZW-6-052 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers.
    ZW-6-052
  • HY-P990084
    Veligrotug 2728655-31-8 99.25%
    Veligrotug (AVE1642) is a selective, fully human IGF-1R antagonist antibody with a Kd value of 0.55 nM for hIGF-1R. Veligrotug blocks the phosphorylation of downstream AKT. Veligrotug is applicable to research related to thyroid eye disease.
    Veligrotug
  • HY-156135
    NSC194598 5358-76-9 98.90%
    NSC194598 is a p53 DNA-binding inhibitor with an IC50 value of 180 nM. NSC194598 inhibits p53 DNA binding and induction of target genesn when p53 is stabilized and activated by irradiation or chemotherapy. NSC194598 can interfere with transcriptional activation of mutated rearranged during transfection (RET) gene, induce apoptosis and G0/G1 phase arrest. NSC194598 can be used for the researches of acute radiation toxicity and medullary thyroid carcinoma.
    NSC194598
  • HY-114557
    NSC 90469 1041-01-6 99.41%
    NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity.
    NSC 90469
  • HY-129046D
    RNase A, Recombinant 9001-99-4
    RNase A (Bovine pancreatic RNase) is a widely used Endonuclease in DNA purification by specifically hydrolyzing cytosine or uracil residues of RNA. RNase A degrades the RNA in the RNA/DNA duplex. RNase A catalyses the breakdown of 3',5'-phosphodiester linkages of single stranded RNA. RNase A family members in organisms are tightly involved in various physiological and pathological processes including cell growth and development, proliferation, differentiation and migration. Dysregulation of RNase A activity or expression level is closely related to pancreatic, ovarian, bladder and thyroid cancer. RNase A has tumor cell-killing ability. RNase A, Recombinant (Ribonuclease A, Recombinant) is a recombinant form of RNase A.
    RNase A, Recombinant
  • HY-N10348
    Progoitrin 585-95-5 98.72%
    Progoitrin is a sulfur-containing glucosinolate, as well as a naturally occurring orally active thioglycoside. Progoitrin acts as a hepatotoxin and antithyroid agent. Progoitrin is quantitatively converted to goitrin in vivo, including via a gastrointestinal hydrolysis pathway that does not require exogenous myrosinase, thereby blocking the organification of iodine in the thyroid gland and inhibiting the uptake and accumulation of radioactive iodine. Progoitrin can be used in studies related to Graves' disease.
    Progoitrin
  • HY-125946
    Latanoprost lactone diol 145667-75-0 99.86%
    Latanoprost lactone diol is a small organic molecule derived from Prostaglandin F2α (HY-12956), serving as a key synthetic intermediate and inactive metabolism-related form of Latanoprost (HY-B0577). Latanoprost lactone diol is significantly upregulated in hypothyroid rats, and its level can be reversed by crude polysaccharide, lactone and oligosaccharide fractions from the rhizome of Atractylodis macrocephalae. Latanoprost lactone diol can be used in studies related to hypothyroidism.
    Latanoprost lactone diol
  • HY-183783
    PROTAC RET Degrader 2
    PROTAC RET Degrader 2 is a RET degrader with a target IC50 of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma.
    PROTAC RET Degrader 2
  • HY-183729
    RET-IN-34 2222758-09-8
    RET-IN-34 (Compound EV1) is a RET inhibitor with an IC50 of 0.89 nM. RET-IN-34 serves as a target protein ligand for PROTAC synthesis (Ligand for Target Protein for PROTAC). RET-IN-34 is applicable for the synthesis of PROTAC RET Degrader 2 (HY-183783). RET-IN-34 exhibits anticancer activity against medullary thyroid carcinoma. RET-IN-34 can be used in studies related to medullary thyroid carcinoma.
    RET-IN-34
  • HY-183628
    MEAP
    MEAP (2-(4-Morpholinoanilino-6-[(2-exo-norbornyl) amino)-purine) is a NEDD9-STAT3 modulator. MEAP disrupts NEDD9-STAT3 interaction, driving STAT3 Y705 dephosphorylation. MEAP induces G2/M phase arrest. MEAP can be used for the research of anaplastic thyroid cancer.
    MEAP
  • HY-182741
    RET-IN-32 2620629-32-3
    RET-IN-32 is an orally active RET inhibitor with IC50 values of 0.285, 4.602 and 103.5 nM against wild-type, V804M and G810S mutant forms, respectively. RET-IN-32 inhibits the autophosphorylation of Tyr1062. RET-IN-32 completely suppresses tumor growth induced by BAF3-KIF3B-RET-WT xenografts. RET-IN-32 can be used in the research of thyroid cancer and lung cancer.
    RET-IN-32
  • HY-N16764
    (rel)-Salcolin A 1977557-69-9
    (rel)-Salcolin A is a flavonoid lignan compound with anticancer, anti-inflammatory, and neuroprotective activities. (rel)-Salcolin A has IC50 values ??of 66.69 μM and 56.12 μM against anaplastic thyroid carcinoma cells (HTH83) and papillary thyroid carcinoma cells (TPC1), respectively. (rel)-Salcolin A also inhibits LPS-induced NO production with an IC50 of 14.65 μM. (rel)-Salcolin A exerts its effects by inducing necroptosis in thyroid cancer cells, inhibiting the production of the inflammatory factor NO, and protecting against glutamate-induced neuronal cell damage, with a neuroprotective E50 of 47.44 μM. (rel)-Salcolin A can be used in research related to thyroid cancer, anti-inflammation, and neuroprotection. (rel)-Salcolin A can be naturally extracted from the leaves of Casearia arborea and the stems of Zea mays (corn).
    (rel)-Salcolin A
  • HY-N16905
    Diosbulbin I 1187951-05-8
    Diosbulbin I is a furan-type nor-diterpenoid compound that can be naturally extracted from the tubers of Dioscorea bulbifera L. Dioscorea bulbifera L. is traditionally used to research thyroid diseases and tumors.
    Diosbulbin I